Tharimmune (THAR) announced the appointment of James Gordon Liddy as a strategic advisor. Mr. Liddy, an internationally recognized expert on counterterrorism and critical infrastructure protection, will provide guidance as Tharimmune advances the development of TH104, its lead program for temporary prophylaxis against respiratory and/or central nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids, including potential weaponized agents like fentanyl. As the Senior Advisor to the Director for Strategy, Policy and Initiatives for the Office of the Assistant Secretary of Defense for Special Operations and Low Intensity Conflict, and previously the Chief of Plans and Policy for the United States Special Operations Command’s Washington Office, Liddy played a pivotal role in designing and coordinating policy, operational plans, and strategic initiatives for the Global War on Terrorism.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THAR:
- Tharimmune releases pharmacokinetic, metabolism data from TH104 study
- Tharimmune presents clinical data on TH104 metabolic profile
- Biotech Alert: Searches spiking for these stocks today
- Tharimmune appoints Clay Kahler, Gary Stetz to board of directors
- Tharimmune announces FDA feedback on TH104 for prophylaxis